Blood Coagulation and Fibrin Clot Complexes

The Thrombin–fibrinogen / fibrin–integrin / fibrin–FXIIIa complexes represent the essential molecular interactions involved in the final common pathway of blood coagulation and thrombus stabilization (StatPearls, NBK482253). Thrombin (Factor IIa) initiates the process by cleaving soluble fibrinogen into fibrin monomers, which spontaneously polymerize into a structural mesh (UniProt P00734, P02671). This fibrin network then binds to the platelet-specific integrin alpha-IIb/beta-3 (GPIIb/IIIa), facilitating platelet aggregation and anchoring the clot to the site of vascular injury (UniProt P08514). To ensure mechanical stability, Factor XIIIa (FXIIIa) catalyzes the formation of covalent cross-links between fibrin chains, protecting the clot from premature fibrinolysis (UniProt P00488). These complexes are central to physiological hemostasis but are also the primary drivers of pathological conditions such as myocardial infarction, ischemic stroke, and venous thromboembolism. Consequently, they are major therapeutic targets for a wide range of drugs, including anticoagulants that inhibit thrombin, antiplatelets that block integrin receptors, and thrombolytics that degrade the fibrin matrix (PubMed, PMID: 30033743). Therapeutic intervention in these pathways requires a delicate balance to prevent thrombosis while minimizing the risk of life-threatening hemorrhage.

Other names

Thrombin–fibrinogen / fibrin–integrin / fibrin–FXIIIa complexesFibrin clot assemblyHemostatic plug componentsThrombin-Fibrinogen-Fibrin-Integrin-FXIIIa axisFibrinogen-Fibrin-Thrombin-FXIIIa-Integrin alpha-IIb/beta-3 complex

Inhibition of thrombin-mediated fibrinogen cleavage, competitive blockade of fibrin-integrin binding on platelets, or enzymatic degradation of the cross-linked fibrin matrix.